Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) With Lenalidomide (R) Maintenance Versus R Maintenance Alone in Adult Patients With Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response to Autologous Stem Cell Transplantation (ASCT): Phase 3 KarMMa-9 Trial
Year: 2024
Type: article
Authors: Noopur Raje, Adam D. Cohen, Simon J. Harrison, Shaji Kumar, Aurore Perrot, Fredrik Schjesvold, Hermann Einsele, Paula Rodríguez-Otero, Ingerid Weum Abrahamsen, Carlos Fernández de Larrea, Rik Schots, Anna Truppel- Hartmann, Shafqat Inam, Fan Wu, Xiaobo Zhong, Thomas Finocchio, Mihaela Popa McKiver, Mark Cook, María-Victoria Mateos
Institutions: Massachusetts General Hospital, University of Pennsylvania, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Mayo Clinic, Université de Toulouse, Oslo University Hospital, University of Oslo, University of Würzburg, Clinica Universidad de Navarra, Hospital Clínic de Barcelona, Universitair Ziekenhuis Brussel, Alfred Health, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland), Complejo Hospitalario de Salamanca
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401876699